ABC	adenosine triphosphate-binding cassette
ADC	antibody–drug conjugate
ADCC	antibody-dependent cytotoxicity
ALCL	anaplastic large-cell lymphoma
ALL	acute lymphocytic leukaemia
AML	acute myeloid leukaemia
ASCT	autologous stem cell transplantation
CDC	complement-dependent cytotoxicity
CR	complete response
CTLA-4	cytotoxic T lymphocyte-associated protein-4
DAR	drug to antibody ratio
DLBCL	diffuse large B-cell lymphoma
EGFR	epidermal growth factor receptor
EGFRvIII	epidermal growth factor receptor mutant (exon deletion 2–7)
FDA	Food and Drug Administration
FL	follicular lymphoma
GBM	glioblastoma multiforme
GPNMB	glycoprotein-NMB
HER2	epidermal growth factor receptor 2
HL	Hodgkin lymphoma
iNHL	indolent Non-Hodgkin lymphoma
mAb	monoclonal antibody
MBC	metastatic breast cancer
mc	Maleimidocaproyl
mcc	Maleimidomethyl cyclohexane-1-carboxylate, linked to cysteine of mAb
MCC	Maleimidomethyl cyclohexane-1-carboxylate, linked to thiol of cytotoxin
MDR	multidrug resistance
MMAE	monomethylauristatin E
MMAF	monomethylauristatin F
MMTV	mouse mammary tumour virus
NHL	non-Hodgkin lymphoma
NSCLC	non-small cell lung cancer
ORR	overall response rate
P-gp	P-glycoprotein
PABC	Para-aminobenzyloxycarbonyl
PBD	pyrrolobenzodiazepine
PD-1	programmed cell death protein-1
RCC	renal cell cancer
sALCL	systemic anaplastic large-cell lymphoma
SCLC	small cell lung cancer
SPDB	N-succinimidyl-4-(2-pyridyldithio) butanoate
T-DM1	Ado-trastuzumab emtansine
TM-ADC	trastuzumab-maytansinoid ADC
TICs	tumour initiating cells
TILs	infiltrating lymphocytes
vc	valine-citrulline
vc-seco-DUBA	valine-citrulline-seco duocarmycin hydroxybenzamide azaindole